BC
ACAD icon

Bayforest Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Bayforest Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,224
Closed -$69.5K – 719
2025
Q2 		$69.5K Sell
3,224
-9,805
-75% -$182K 0.03% 508
2025
Q1 		$216K Sell
13,029
-4,419
-25% -$80.3K 0.09% 376
2024
Q4 		$320K Buy
+17,448
New +$282K 0.4% 27

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Bayforest Capital's ACAD Position: Q3 2025 in Review

Bayforest Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 3,224 shares — an estimated $69.5K sold.

Bayforest Capital first reported a position in ACAD in Q4 2024 and held it in 3 quarters. The position peaked at $320K in Q4 2024. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Bayforest Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bayforest Capital sold 3,224 Acadia Pharmaceuticals shares in Q3 2025, an estimated $69.5K.
  • Bayforest Capital first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Bayforest Capital's Acadia Pharmaceuticals position peaked at $320K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Bayforest Capital's 13F filing for Q3 2025, filed 24 Oct 2025.